ADP-receptor blockade: A case for personalised pharmacotherapy?

Summary

The dual antiplatelet therapy consisting of aspirin and the ADP-receptor blocker clopidogrel is the current standard medication after acute coronary events. However, clopidogrel is characterised by a high interindividual response variability, insufficient inhibition of platelet aggregation in a significant number of patients, relatively slow onset of efficacy and potential interaction with different co-medication via diverse hepatic cytochrome enzymes. In various trials, response variability of clopidogrel was translated into a higher rate of recurrent cardiovascular events. Different clinical and non-genetic factors contribute to the phenomenon of clopidogrel response variability. An individualised antithrombotic pharmacotherapy taking these factors into account, including the definition of status of response, verification of the efficacy by standardised platelet function testing, intensified or alternative platelet inhibition would be the ultimate goal for patients treated with clopidogrel. Currently, new drugs are on the way and promise a more consistent efficacy and smaller amount of response variability. However, the bleeding risk in subgroups of patients and further side effect profile remains to be clearly defined. Therefore, risk stratification models are warranted to identify patients who benefit from personalised pharmacotherapy in terms of improved clinical net benefit. In this review, we discuss treatment failure of clopidogrel based on platelet function testing, the mechanism of established and new ADP-blockers as well as new therapeutic principles.

Keywords

ADP-receptor blockers - thienopyridines - clopidogrel - response variability - prasugrel - platelet function testing

• References

• 1 Gershlick AH. Antiplatelet therapy. Hosp Med 2000; 61: 15-23.
• 2 Schrör K. Antiplatelets drugs. A comparative review. Drugs 1995; 50: 7-28.
• 3 Harker LA, Bruno JJ. Ticlopidine’s mechanism of action on human platelets. In: Ticlopidine, Platelets and Vascular Disease. New York: Springer; 1993. pp. 99-116.
• 4 Herbert JM, Frehel D, Vellee E. et al. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993; 11: 180-198.
• 5 Bertrand ME, Rupprecht HJ, Urban P. et al CLASSICS Investigators.. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102: 624-629.
• 6 Yusuf S, Zhao F, Mehta SR. et al. Clopidogrel in unstable angina to prevent recurrent events trial investiagators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
• 7 King SB, 3rd Smith SC, Jr Hirshfeld JW. Jr, et al. 2007 focused update of the ACC/ AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report if the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008; 51: 172-209.
• 8 Sabatine MS, Cannon CP, Gibson CM. et al. CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-1189.
• 9 Gawaz M. Blood platelets: physiology, pathophysiology, membrane receptors, antiplatelet drugs, coronary heart disease, stroke, peripheral arterial disease. Stuttgart: Thieme; 2001
• 10 Storey RF, Newby LJ, Heptinstall S. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 2001; 12: 443-447.
• 11 Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001; 86: 222-232.
• 12 Cattaneo M. Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert Rev Cardiovasc Ther 2007; 5: 45-55.
• 13 Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 2008; 99: 466-472.
• 14 Storey RF. Biology and pharmacology of the platelet P2Y₁₂ receptor. Curr Pharm Des 2006; 12: 1255-1259.
• 15 Taubert D, von Beckerath N, Grimberg G. et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006; 80: 486-501.
• 16 Angiolillo DJ, Fernandez-Oritz A, Bernardo E. et al. Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505-1516.
• 17 Gurbel PA, Bliden KP, Hiatt BL. et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
• 18 Gurbel PA, Bliden KP. Platelet activation after stenting with heparin-coated versus non-coated stents. Am Heart J 2003; 146: E10.
• 19 Muller I, Besta F, Schulz C. et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783-787.
• 20 Matetzky S, Shenkman B, Guetta V. et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
• 21 Ferreiro JL, Angiolillo DJ. Clopidogrel response variability: current status and future directions. Thromb Haemost 2009; 102: 7-14.
• 22 Angiolillo DJ, Suryadevara S, Capranzano P. et al. Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists. Catheter Cardiovasc Interv 2009; 73: 1-14.
• 23 Geisler T, Langer H, Wydymus M. et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27: 2420-2425.
• 24 Ho PM, Maddox TM, Wang L. et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-944.
• 25 Lev EI, Patel RT, Maresh KJ. et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006; 47: 27-33.
• 26 Gurbel PA, Bliden KP, Hayes KM. et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005; 45: 1392-1396.
• 27 Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 2005; 115: 101-108.
• 28 Hochholzer W, Trenk D, Bestehorn HP. et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent implantation. J Am Coll Cardiol 2006; 48: 1742-1750.
• 29 Sibbing D, Braun S, Morath T. et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849-856.
• 30 Geisler T, Rapin M, Zürn C. et al. Sub-acute but not late stent thrombosis is associated with post-interventional residual platelet aggregation in patients undergoing coronary stenting. Clin Res Cardiol 2009; 98 (Suppl. 01) V1683.
• 31 Siller-Matula JM, Christ G, Lang IM. et al. Multiple Electrode Aggregometry better predicts stent thrombosis than VASP assay. J THromb Haemost. 2009 epub ahead of print.
• 32 Schäfer A, Weinberger S, Flierl U. et al. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y₁₂-specific assay. Thromb Haemost 2008; 100: 618-625.
• 33 Jakubowski JA, Payne CD, Li YG. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessment by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost 2007; 99: 215-222.
• 34 Pampuch A, Cerletti C, de Gaetano G. et al. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y₁₂ receptor. Thromb Haemost 2006; 96: 767-773.
• 35 Aleil B, Ravanat C, Cazenave JP. et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3: 85-92.
• 36 Jakubowski JA, Payne CD, Li GY. et al. The use of the VerifyNow P2Y₁₂ point-of-care device to monitor platelet function across a range of P2Y₁₂ inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost 2008; 99: 409-415.
• 37 Sibbing D, Schulz S, Braun S. et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost. 2009 epub ahead of print.
• 38 Sibbing D, Braun S, Jawansky S. et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 2008; 99: 121-126.
• 39 Chen ZM, Jiang LX, Chen YP. et al. COMMIT (Clopidogrel and metoprolol in myocardial infarction trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005; 366: 1607-1621.
• 40 Serebruany VL, Shalito I, Kopyleva O. Prasugrel development- claims and achievements. Thromb Haemost 2009; 101: 14-22.
• 41 Geisler T, Grass D, Bigalke B. et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost. 2008; 6: 54-61.
• 42 Angiolillo DJ, Bernardo E, Ramirez C. et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 2006; 48: 298-304.
• 43 Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54: 2430-2435.
• 44 Geisler T, Anders N, Paterok M. et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007; 30: 372-374.
• 45 Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?. J Invasive Cardiol 2004; 16: 169-174.
• 46 Sibbing D, von Beckerath O, Schömig A. et al. Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am J Cardiol 2007; 100: 203-205.
• 47 Farid NA, Payne CD, Small DS. et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007; 81: 735-741.
• 48 Lau WC, Waskell LA, Watkins PB. et al. Atorvastatin reduced the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 107: 32-37.
• 49 Gilard M, Arnaud B, Cornily JC. et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-bling OCLA (Omeprazole Clopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-260.
• 50 Juurlink DN, Gomes T, Ko DT. et al. A population-based study of the drug interaction between proton pump inhibitors and clopdiogrel. CMAJ 2009; 180: 713-718.
• 51 Siller-Matula JM, Lang I, Christ G. et al. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol. 2008; 52: 1557-1563.
• 52 Kleiman NS. Clopidogrel and calcium-channel antagonists: another drug-drug interaction for the ever-wary clinician?. J Am Coll Cardiol 2008; 52: 1564-156.
• 53 Geisler T, Zuern C, Paterok M. et al. Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy. Eur Heart J 2008; 29: 1635-1643.
• 54 Zuern CS, Geisler T, Lutilsky N. et al. Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy. Thromb Res. 2009 epub ahead of print.
• 55 Sibbing D, Morath T Stegherr J. et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101: 714-719.
• 56 Taubert D, Kastrati A, Harlfinger S. et al. Pharmacogenetis of clopidogrel after administration of a high loading dose. Thromb Haemost 2004; 92: 311-316.
• 57 Angiolillo DJ, Bernardo Trabetti E. et al. Role of the C1236T (rs1128503) polymorphism of the MDR-1 gene on clopidogrel responsiveness. J Am Coll Cardiol 2008; (Suppl) 51: A301.
• 58 Simon T, Verstuyft C, Mary-Krause M. et al. French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-375.
• 59 Cuisset T, Frere C, Quilici J. et al. Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome. Thromb Haemost 2007; 97: 212-217.
• 60 Bal dit Sollier C, Berge N, Boval B. et al. Functional variability of platelet response to clopidogrel correlates with P2Y₁₂ receptor occupancy. Thromb Haemost 2009; 101: 116-122.
• 61 Mega JL, Close SL, Wiviott SD. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
• 62 Trenk D, Hochholzer W, Fromm MF. et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008; 51: 1925-2008.
• 63 Brandt JT, Close SL, Iturria SJ. et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007; 5: 2429-2436.
• 64 Hulot JS, Bura V, Villard E. et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244-2247.
• 65 Collet JP, Hulot JS, Pena A. et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373: 309-317.
• 66 Geisler T, Schaeffeler E, Dippon J. et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 2008; 9: 1251-1259.
• 67 Lau WC, Gurbel PA, Watkins PB. et al. Contribution of hepatic cytochrome P4503A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004; 109: 166-171.
• 68 Müller I, Seyfarth M, Rüdiger S. et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001; 85: 92-93.
• 69 Von Beckerath N, Taubert D, Pogatsa-Murray G. et al. Absportion, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg dose of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005; 112: 2946-2950.
• 70 Angiolillo DJ, Fernandez-Ortiz A, Bernardo E. et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 2004; 25: 1903-1910.
• 71 Angiolillo DJ, Bernardo E, Palazuelos J. et al. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study. Thromb Haemost 2008; 99: 161-168.
• 72 Angiolillo DJ, Shoemaker SB, Desai B. et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007; 115: 708-716.
• 73 Anderson JL, Adams CD, Antman EM. et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task force on practice guidelines (Writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction) developed in collaboration with the American college of emergency physicians, the society for cardiovascular angiographiy and interventions, and the society of thoracic surgeons endorsed by the American association of cardiovascular and pulmonary rehabilitation and the society of academic emergency medicine. J Am Coll Cardiol 2007; 50: e1-e157.
• 74 Bassand JP, Hamm CW, Ardissino D. et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598-1660.
• 75 Neubauer H, Lask S, Engelhardt A. et al. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. Thromb Haemost 2008; 99: 357-362.
• 76 Bonello L, Camoin-Jau L, Arques S. et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance. J Am Coll Cardiol 2008; 51: 1404-1411.
• 77 Bonello L, Camoin-Jau L, Armero S. et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009; 103: 5-10.
• 78 Lordkipanidzé M, Pharand C, Nguyen TA. et al. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J 2008; 29: 2877-2885.
• 79 Jernberg T, Payne CD, Winters KJ. et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27: 1166-1173.
• 80 Beguin S, Keularts I. On the coagulation of platelet-rich plasma. Physiological mechanism and pharmacological consequences. Haemostasis 1999; 29: 50-57.
• 81 Wong PC, Crain EJ, Watson CA. et al. Clopidogrel versus prasugrel in rabbits. Thromb Haemost 2009; 101: 108-115.
• 82 Brandt JT, Payne CD, Wiviott SD. et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007; 153: 66.e9-16.
• 83 Wiviott SD, Antman EM, Winters KJ. et al JUMBO-TIMI 26 Investigators.. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y₁₂ antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005; 111: 3366-3373.
• 84 Wiviott SD, Braunwald E, McCabe CH. et al. Prasugrel vs clopigogrel in patients with acute coronary syndromes. N Eng J Med 2007; 357: 2001-2015.
• 85 Serebruany VL, Makarov LM. Future of oral antiplatelet therapy: four challenged hypotheses. Thromb Haemost 2009; 101: 1041-1043.
• 86 Lansky AJ, Tsuchiya Y, Brener M. et al. Comparison between ticlopidine and clopidogrel in patients undergoing promary stenting in acute myocardial infarction: results from the CADILLAC trial. Catheter Cardiovasc Interv 2008; 72: 917-924.
• 87 Wiviott SD, Trenk D, Frelinger AL. et al. PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116: 2923-2932.
• 88 Small DS, Farid NA, Payne CD. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008; 48: 475-484.
• 89 Calatzis A. Another view of prasugrel. Thromb Haemost 2009; 101: 12-13.
• 90 Gretler DD, Conley PB, Andre P. et al. “First in human” experience with PRT060128, a new direct-acting, reversible, P2Y₁₂ inhibitor for IV and oral use. J Am Coll Cardiol 2007; 49 (Suppl. 02) 326A.
• 91 A Randomized trial to evaluate the effect of anjunctive antiplatelet therapy with intravenous PRT060128, a selective P2Y₁₂-receptor inhibitor, before primary percutaneous intervention in patients with ST-elevation myocardial infarction. NCT00546260. Accessed at www.clinicaltrials.gov.
• 92 A randomized, double-blind, active-controlled trial to evaluate intravenous and oral PRT060128, a selective and reversible P2Y₁₂ inhibitor, vs clopidogrel, as a novel antiplatelet therapy in patients undergoing non-urgent PCI. NCT00751231. Accessed at www.clinicaltrials.gov.
• 93 Storey RF, Husted S, Harrington RA. et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y₁₂ receptor antagonist, compared with clopidogrel in patients with acute coronary syndrome. J Am Coll Cariol 2007; 50: 1852-1856.
• 94 Cannon CP, Husted S, Harrington RA. et al. DISPERSE-2 Investigators. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with nonST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007; 50: 1844-1851.
• 95 Wallentin L, Becker RC, Budaj A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
• 96 Houston D, Costanzi S, Jabobson KA. et al. Development of selective high affinity antagonists, agonists, and radioligands for the P2Y1 receptor. Comb Chem High Throughput Scr 2008; 11: 410-419.